Biostatistician Abisola Idu, MS, MPH, is interested in research that investigates the effectiveness and efficacy of treatment in pharmacoepidemiologic studies. She has a broad range of interest in research with a strong motivation to investigate the health challenges of malaria, obesity, cancer, heart disease, and maternal health.
Ms. Idu began her contributions to clinical and public health research through her academic training at the University of Texas Health Science Center, School of Public Health. She further got rigorous research experience by being a part of the leukemia, lymphoma, and cancer prevention research team at The University of Texas M.D. Anderson Cancer Center in 2015. She has been a biostatistician at Kaiser Permanente Washington Health Research Institute's Biostatistics Unit since 2018.
Ms. Idu looks forward to using her expertise in application of epidemiological principles and surveillance methodologies at KPWHRI. She has an in-depth knowledge of the ICH-GCP, FDA, IRB policies, regulations, and guidelines and plans to use her skills and background to implement epidemiologic study designs in clinical research studies.
Efficacy and safety of therapies; association between genetic variability and survival outcomes
Role of nutritional, psychological and lifestyle factors; obesity prevention and control
Role of aging, nutritional and lifestyle factors; Intervention strategies for prevention and disease control
Association between social, behavioral and clinical factors and maternal and infant outcomes
Malaria prevention and control; development of vaccines; availability and accessibility to malaria treatment
Wartko PD, Qiu H, Idu AE, Yu O, McCormack J, Matthews AG, Bobb JF, Saxon AJ, Campbell CI, Liu D, Braciszewski JM, Murphy SM, Burganowski RP, Murphy MT, Horigian VE, Hamilton LK, Lee AK, Boudreau DM, Bradley KA. Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: comparison of trial and non-trial clinics in the same health systems. BMC Health Serv Res. 2022 Dec 29;22(1):1593. doi: 10.1186/s12913-022-08915-1. PubMed
Coley RY, Smith JJ, Karliner L, Idu AE, Lee SJ, Fuller S, Lam R, Barnes DE, Dublin S. External validation of the eRADAR risk score for detecting undiagnosed dementia in two real-world healthcare systems. J Gen Intern Med. 2022 Jul 29. doi: 10.1007/s11606-022-07736-6. Online ahead of print. PubMed
Braciszewski JM, Idu AE, Yarborough BJH, Stumbo SP, Bobb JF, Bradley KA, Rossom RC, Murphy MT, Binswanger IA, Campbell CI, Glass JE, Matson TE, Lapham GT, Loree AM, Barbosa-Leiker C, Hatch MA, Tsui JI, Arnsten JH, Stotts A, Horigian V, Hutcheson R, Bart G, Saxon AJ, Thakral M, Ling Grant D, Pflugeisen CM, Usaga I, Madziwa LT, Silva A, Boudreau DM. Sex differences in comorbid mental and substance use disorders among primary care patients with opioid use disorder. Psychiatr Serv. 2022 Jun 16:appips202100665. doi: 10.1176/appi.ps.202100665. Online ahead of print. PubMed
Dublin S, Idu A, Avalos LA, Cheetham TC, Easterling TR, Chen L, Holt VL, Nance N, Bider-Canfield Z, Neugebauer RS, Reynolds K, Badon SE, Shortreed SM. Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: a retrospective cohort study. PLoS One. 2022 May 16;17(5):e0268284. doi: 10.1371/journal.pone.0268284. eCollection 2022. PubMed
Shortreed SM, Gray R, Akosile MA, Walker RL, Fuller S, Temposky L, Fortmann SP, Albertson-Junkans L, Floyd JS, Bayliss EA, Harrington LB, Lee MH, Dublin S. Increased COVID-19 infection risk drives racial and ethnic disparities in severe COVID-19 outcomes. J Racial Ethn Health Disparities. 2022 Jan 24. doi: 10.1007/s40615-021-01205-2. [Epub ahead of print]. PubMed
Pocobelli G, Akosile MA, Hansen RN, Eavey J, Wellman RD, Johnson RL, Carls G, Bron M, Dublin S. Obstructive sleep apnea and risk of motor vehicle accident. Sleep Med. 2021 Jul 17;85:196-203. doi: 10.1016/j.sleep.2021.07.019. [Epub ahead of print]. PubMed
In a new study, a tool to help discover undiagnosed dementia performed well in 2 separate health systems.
A study led by Dr. Sascha Dublin finds similar outcomes for 3 hypertension medications, filling an evidence gap.
New work by Susan Shortreed, PhD, finds infection risks drive worse outcomes for some racial and ethnic groups.